Our main product：
Zilia has developed an innovative, non-invasive platform technology that uses imaging, spectrometry and artificial intelligence to measure, quantitatively and in real-time, different biomarkers in the human eye. Zilia’s first product, Zilia Ocular, quantifies oxygen saturation, a crucial factor in three of the most prevalent diseases of the eye: glaucoma, diabetic retinopathy and age-related macular degeneration. By generating new, accurate insights about the eye’s metabolic activity, Zilia aims to revolutionize the prevention, diagnosis and management of these potentially blinding ocular diseases.
While Zilia’s first product is developed for the eye care market, potential applications of ocular oximetry go well beyond eye care. Indeed, the assessment of this biomarker may generate key findings in neurology, cardiology, intensive care, and drug research. In addition, because the eye is a unique window into a person’s health, Zilia’s platform technology can be adapted to assess a vast array of biomarkers present in the eye, thereby opening the door to an even broader range of investigations, applications and markets.

Advantages of our technology：
Zilia’s technology is based on imaging and spectrometry. It relies on a patented device coupled with a proprietary web-based software. The patient is placed in front of the device and looks at a fixation target. Light emitted from the device travels through the eye, reflects on the retina, and returns to provide both a series of images and spectra. These spectra are analyzed in real-time to enable oxygen saturation measurements at the targeted location. Unlike any other technology, the Zilia Ocular has the capability to provide static and dynamic measurements at various locations in the eye fundus, providing completely new data sets to eyecare professionals.

URL：
https://ziliahealth.com/